Lynch syndrome cancer vaccines: a roadmap for the development of precision immunoprevention strategies
Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 March 2023
|
| In: |
Frontiers in oncology
Year: 2023, Volume: 13, Pages: 1-17 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2023.1147590 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2023.1147590 Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2023.1147590 
|
| Author Notes: | Shizuko Sei, Aysel Ahadova, Derin B. Keskin, Lena Bohaumilitzky, Johannes Gebert, Magnus von Knebel Doeberitz, Steven M. Lipkin and Matthias Kloor |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1847477968 | ||
| 003 | DE-627 | ||
| 005 | 20230713140825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230606s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2023.1147590 |2 doi | |
| 035 | |a (DE-627)1847477968 | ||
| 035 | |a (DE-599)KXP1847477968 | ||
| 035 | |a (OCoLC)1389529815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sei, Shizuko |e VerfasserIn |0 (DE-588)1292115157 |0 (DE-627)1847487920 |4 aut | |
| 245 | 1 | 0 | |a Lynch syndrome cancer vaccines |b a roadmap for the development of precision immunoprevention strategies |c Shizuko Sei, Aysel Ahadova, Derin B. Keskin, Lena Bohaumilitzky, Johannes Gebert, Magnus von Knebel Doeberitz, Steven M. Lipkin and Matthias Kloor |
| 264 | 1 | |c 22 March 2023 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.06.2023 | ||
| 520 | |a Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous lesions, cancer-risk reduction strategies are still centered around endoscopic or surgical removal of neoplastic lesions and susceptible organs. Safe and effective cancer prevention strategies are critically needed to improve the life quality and longevity of LS and other HCS carriers. The era of precision oncology driven by recent technological advances in tumor molecular profiling and a better understanding of genetic risk factors has transformed cancer prevention approaches for at-risk individuals, including LS carriers. MMR deficiency leads to the accumulation of insertion and deletion mutations in microsatellites (MS), which are particularly prone to DNA polymerase slippage during DNA replication. Mutations in coding MS give rise to frameshift peptides (FSP) that are recognized by the immune system as neoantigens. Due to clonal evolution, LS tumors share a set of recurrent and predictable FSP neoantigens in the same and in different LS patients. Cancer vaccines composed of commonly recurring FSP neoantigens selected through prediction algorithms have been clinically evaluated in LS carriers and proven safe and immunogenic. Preclinically analogous FSP vaccines have been shown to elicit FSP-directed immune responses and exert tumor-preventive efficacy in murine models of LS. While the immunopreventive efficacy of “off-the-shelf” vaccines consisting of commonly recurring FSP antigens is currently investigated in LS clinical trials, the feasibility and utility of personalized FSP vaccines with individual HLA-restricted epitopes are being explored for more precise targeting. Here, we discuss recent advances in precision cancer immunoprevention approaches, emerging enabling technologies, research gaps, and implementation barriers toward clinical translation of risk-tailored prevention strategies for LS carriers. We will also discuss the feasibility and practicality of next-generation cancer vaccines that are based on personalized immunogenic epitopes for precision cancer immunoprevention. | ||
| 700 | 1 | |a Ahadova, Aysel |d 1988- |e VerfasserIn |0 (DE-588)106835268X |0 (DE-627)820167118 |0 (DE-576)427724783 |4 aut | |
| 700 | 1 | |a Keskin, Derin B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bohaumilitzky, Lena |d 1993- |e VerfasserIn |0 (DE-588)1166676250 |0 (DE-627)103054736X |0 (DE-576)510845487 |4 aut | |
| 700 | 1 | |a Gebert, Johannes |e VerfasserIn |0 (DE-588)1033923567 |0 (DE-627)743674731 |0 (DE-576)381600688 |4 aut | |
| 700 | 1 | |a Knebel Doeberitz, Magnus von |e VerfasserIn |0 (DE-588)1022165291 |0 (DE-627)71693289X |0 (DE-576)364934239 |4 aut | |
| 700 | 1 | |a Lipkin, Steven M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kloor, Matthias |d 1972- |e VerfasserIn |0 (DE-588)124552803 |0 (DE-627)363416609 |0 (DE-576)294228616 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 13(2023) vom: März, Artikel-ID 1147590, Seite 1-17 |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a Lynch syndrome cancer vaccines a roadmap for the development of precision immunoprevention strategies |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g month:03 |g elocationid:1147590 |g pages:1-17 |g extent:17 |a Lynch syndrome cancer vaccines a roadmap for the development of precision immunoprevention strategies |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2023.1147590 |x Resolving-System |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2023.1147590 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230606 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 124552803 |a Kloor, Matthias |m 124552803:Kloor, Matthias |d 910000 |d 912000 |d 50000 |e 910000PK124552803 |e 912000PK124552803 |e 50000PK124552803 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 8 |y j | ||
| 998 | |g 1022165291 |a Knebel Doeberitz, Magnus von |m 1022165291:Knebel Doeberitz, Magnus von |d 50000 |e 50000PK1022165291 |k 0/50000/ |p 6 | ||
| 998 | |g 1033923567 |a Gebert, Johannes |m 1033923567:Gebert, Johannes |d 910000 |d 912000 |e 910000PG1033923567 |e 912000PG1033923567 |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 998 | |g 1166676250 |a Bohaumilitzky, Lena |m 1166676250:Bohaumilitzky, Lena |d 50000 |e 50000PB1166676250 |k 0/50000/ |p 4 | ||
| 998 | |g 106835268X |a Ahadova, Aysel |m 106835268X:Ahadova, Aysel |d 910000 |d 912000 |e 910000PA106835268X |e 912000PA106835268X |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 999 | |a KXP-PPN1847477968 |e 4329619245 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Sei","roleDisplay":"VerfasserIn","role":"aut","given":"Shizuko","display":"Sei, Shizuko"},{"roleDisplay":"VerfasserIn","family":"Ahadova","role":"aut","given":"Aysel","display":"Ahadova, Aysel"},{"display":"Keskin, Derin B.","given":"Derin B.","role":"aut","roleDisplay":"VerfasserIn","family":"Keskin"},{"roleDisplay":"VerfasserIn","family":"Bohaumilitzky","role":"aut","given":"Lena","display":"Bohaumilitzky, Lena"},{"display":"Gebert, Johannes","given":"Johannes","role":"aut","family":"Gebert","roleDisplay":"VerfasserIn"},{"role":"aut","family":"Knebel Doeberitz","roleDisplay":"VerfasserIn","display":"Knebel Doeberitz, Magnus von","given":"Magnus von"},{"family":"Lipkin","roleDisplay":"VerfasserIn","role":"aut","given":"Steven M.","display":"Lipkin, Steven M."},{"given":"Matthias","display":"Kloor, Matthias","family":"Kloor","roleDisplay":"VerfasserIn","role":"aut"}],"note":["Gesehen am 06.06.2023"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"origin":[{"dateIssuedDisp":"22 March 2023","dateIssuedKey":"2023"}],"id":{"doi":["10.3389/fonc.2023.1147590"],"eki":["1847477968"]},"relHost":[{"note":["Gesehen am 07.11.13"],"pubHistory":["2011 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"origin":[{"publisher":"Frontiers Media","publisherPlace":"Lausanne","dateIssuedKey":"2011","dateIssuedDisp":"2011-"}],"id":{"zdb":["2649216-7"],"issn":["2234-943X"],"eki":["684965518"]},"part":{"year":"2023","volume":"13","text":"13(2023) vom: März, Artikel-ID 1147590, Seite 1-17","pages":"1-17","extent":"17"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}],"disp":"Lynch syndrome cancer vaccines a roadmap for the development of precision immunoprevention strategiesFrontiers in oncology","recId":"684965518"}],"name":{"displayForm":["Shizuko Sei, Aysel Ahadova, Derin B. Keskin, Lena Bohaumilitzky, Johannes Gebert, Magnus von Knebel Doeberitz, Steven M. Lipkin and Matthias Kloor"]},"recId":"1847477968","title":[{"title_sort":"Lynch syndrome cancer vaccines","subtitle":"a roadmap for the development of precision immunoprevention strategies","title":"Lynch syndrome cancer vaccines"}],"physDesc":[{"extent":"17 S."}]} | ||
| SRT | |a SEISHIZUKOLYNCHSYNDR2220 | ||